AI Summary & Key Takeaways
AI InsightConclusions: Although the number of patients is small, our study demonstrates that EBV treatment can be safely applied with low complication rates as a bronchoscopic lung volume reduction treatment to the patients that have severe heterogeneous emphysema.
📌 3 Key Takeaways
Özet
Aims: Endobronchial valve (EBV) treatment is one of the main minimally invasive treatment options for emphysema management. In this study, we aimed to evaluate the early term complication rates of patients having severe emphysema and being treated with EBV. Methods: A total of fifteen patients treated with EBV for bronchoscopic lung volume reduction between November 2017 and January 2019 were included in the study. Pretreatment demographic data, pulmonary function results and exercise capacities were recorded. All complications encountered during the first 3-month period after the EBV treatment were evaluated. The status of collateral ventilation was assessed with Chartis system. Implanted valves were appropriately chosen according to the bronchial lumens’ diameter. All patients were discharged after a minimum of 72 hours of observation. Results: Fifteen bronchoscopic lung volume reduction treatment sessions were performed for fifteen patients. All of them were male. The mean age of the patients was 66.7±6.3 years and the mean disease duration was 11.1±3.7 years. A mean of 3.46 valves were implanted per patient. Early complications were observed in five patients (33.3%) during the 3-month follow-up period after the EBV treatment. Of them, three had chronic obstructive pulmonary disease exacerbation, one had pneumothorax, and the last one had pneumonia. Only one patient died due to the early complications of the valve treatment. Conclusions: Although the number of patients is small, our study demonstrates that EBV treatment can be safely applied with low complication rates as a bronchoscopic lung volume reduction treatment to the patients that have severe heterogeneous emphysema.